Navigation Links
PDL BioPharma to Announce Fourth Quarter and Full Year 2009 Financial Results and Hold Conference Call on March 2, 2010
Date:2/22/2010

INCLINE VILLAGE, Nev., Feb. 22 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will hold a conference call and webcast on Tuesday, March 2 at 4:30 p.m. Eastern Time to discuss its financial results for the fourth quarter and full year 2009, and provide a business update. The call and webcast will follow the release of the fourth quarter and full year financial results after market close.

Conference Call Details

To access the live conference call via phone, please dial (866) 831-6291 from the United States and Canada or (617) 213-8860 internationally. The conference ID is 90364858. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through March 3, 2010, and may be accessed by dialing (888) 286-8010 from the United States and Canada or (617) 801-6888 internationally. The replay passcode is 53081878.

To access the live and subsequently archived webcast of the conference call, go to the company's Web site at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.

Back to top

RELATED LINKS
http://www.pdl.com/

'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 27, 2016   Zillion Group today ... technology platform, which specializes in live video consultation. ... digital products, Zillion enables companies to realize the ... to take control of their health. ... – including one-to-one, group and webcast scheduled or ...
(Date:4/27/2016)... Oasmia Pharmaceutical AB (NASDAQ: ... new generation of drugs within human and veterinary ... Paclical/Apealea in the Phase III study that included ... cancer. These preliminary results showed non-inferiority between the ... versus Taxol in combination with carboplatin. In fact, ...
(Date:4/26/2016)... , April 26, 2016 Hill-Rom Holdings, Inc. ... a management presentation at the Deutsche Bank 41 st ... 2:50 p.m. EDT. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas . ... hour after conclusion of the live event and accessible at ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of ... them second place for Tampa’s Best Places to Work. They were ranked in the ... great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We work ...
(Date:4/29/2016)... ... 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- ... A. Potter -- are proud of the recent release of their 2014 in vitro ... SART published the latest verified data for 375 U.S. member clinics. *Preliminary data ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. recently sent representatives ... Petbiotics ™, as they fondly call them. As animal lovers, they were ... their non-profit organizations. Animal rescues across the nation face huge hurdles rescuing animals ...
(Date:4/29/2016)... ... April 29, 2016 , ... HEALTHCAREfirst , the ... services, and Deyta Analytics, recently announced the recipients of the fourth annual Hospice ... as measured from the caregiver’s point of view. The official list of recipients ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... study detailing the company’s use of Microsoft Dynamics GP for one their long-term ... a solution that integrated Dynamics GP with key clinical management systems, and delivered ...
Breaking Medicine News(10 mins):